Detalles de la búsqueda
1.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 22(10): 1403-1415, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34516954
2.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Hematol Oncol
; 39(4): 558-566, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34224180
3.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Br J Haematol
; 189(5): 888-903, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32017044
4.
Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Transplant Cell Ther
; 29(9): 579.e1-579.e10, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37311511
5.
Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study.
Transplant Cell Ther
; 29(1): 60.e1-60.e4, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36182104
6.
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.
J Clin Oncol
; 41(9): 1664-1669, 2023 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36399695
7.
Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia.
Leukemia
; 36(6): 1508-1515, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35422096
8.
Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia.
Blood Adv
; 5(23): 5387-5395, 2021 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34597381
9.
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Leuk Lymphoma
; 62(4): 918-926, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33210570
10.
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
Leukemia
; 35(6): 1631-1642, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980976
11.
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Leukemia
; 35(12): 3455-3465, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34017073
12.
A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort.
Hematol Transfus Cell Ther
; 42(1): 46-53, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31235325
13.
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv
; 4(4): 629-637, 2020 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32074277
14.
Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion.
Blood Adv
; 3(14): 2230-2236, 2019 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31332046
15.
Reply to W.H. Tong et al.
J Clin Oncol
; 41(13): 2451-2453, 2023 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36898064
16.
Evaluation of Preoperative Serum Levels of CA 125 and Expression of p53 in Ovarian Neoplasms: A Prospective Clinicopathological Study in a Tertiary Care Hospital.
J Obstet Gynaecol India
; 66(2): 107-14, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27046964
17.
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Leukemia
; 35(12): 3626, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34475521
18.
A subgroup analysis of JUMP, a phase IIIb, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis in a Brazilian cohort
Hematol., Transfus. Cell Ther. (Impr.)
; 42(1): 46-53, Jan.-Mar. 2020. tab, graf
Artículo
en Inglés
| LILACS | ID: biblio-1090480
Resultados
1 -
18
de 18
1
Próxima >
>>